Spero Therapeutics, Inc.

NASDAQ:SPRO

1.31 (USD) • At close September 6, 2024
Bedrijfsnaam Spero Therapeutics, Inc.
Symbool SPRO
Munteenheid USD
Prijs 1.315
Beurswaarde 71,074,567
Dividendpercentage 0%
52-weken bereik 0.99 - 1.89
Industrie Biotechnology
Sector Healthcare
CEO Mr. Satyavrat Shukla C.F.A.
Website https://sperotherapeutics.com

An error occurred while fetching data.

Over Spero Therapeutics, Inc.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults;

Vergelijkbare Aandelen

IN8bio, Inc. logo

IN8bio, Inc.

INAB

0.304 USD

Neoleukin Therapeutics, Inc. logo

Neoleukin Therapeutics, Inc.

NLTX

3.49 USD

Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc.

COCP

1.7 USD

Ocuphire Pharma, Inc. logo

Ocuphire Pharma, Inc.

OCUP

1.2 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)